Venous Thromboembolism – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：89頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Venous Thromboembolism – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Venous Thromboembolism - Pipeline Review, H2 2012', provides an overview of the Venous Thromboembolism therapeutic pipeline. This report provides information on the therapeutic development for Venous Thromboembolism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Venous Thromboembolism. 'Venous Thromboembolism - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Venous Thromboembolism.
- A review of the Venous Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Venous Thromboembolism pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Venous Thromboembolism therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Venous Thromboembolism - Pipeline Review, H2 2012', provides an overview of the Venous Thromboembolism therapeutic pipeline. This report provides information on the therapeutic development for Venous Thromboembolism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Venous Thromboembolism. 'Venous Thromboembolism - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Venous Thromboembolism.
- A review of the Venous Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Venous Thromboembolism pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Venous Thromboembolism therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Thromboembolism Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Venous Thromboembolism 8
Venous Thromboembolism Therapeutics under Development by Companies 10
Venous Thromboembolism Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Venous Thromboembolism Therapeutics – Products under Development by Companies 18
Venous Thromboembolism Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Venous Thromboembolism Therapeutics Development 20
Bristol-Myers Squibb Company 20
Sanofi-Aventis 21
Daiichi Sankyo Company, Ltd 22
Bayer AG 23
Portola Pharmaceuticals, Inc. 24
Cristalia Produtos Quimicos Farmaceuticos Ltda. 25
Endotis Pharma 26
Regado Biosciences. 27
Venous Thromboembolism – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Lixiana - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Eliquis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Betrixaban - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AVE5026 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AVE5026 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Xarelto - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
EP37151 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
REG2 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Dalteparin Sodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Aspirin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Actiparin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Warfarin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Dalteparin Sodium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Fondaparinux - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Aspirin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Sodium Enoxaparin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Rivaroxaban - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Venous Thromboembolism Therapeutics – Drug Profile Updates 58
Venous Thromboembolism Therapeutics – Discontinued Products 73
Venous Thromboembolism Therapeutics - Dormant Products 75
Venous Thromboembolism – Product Development Milestones 77
Featured News & Press Releases 77
Jul 25, 2012: NICE Recommends Bayer's Xarelto For Treatment Of Blood Clots 77
Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Pradaxa 78
Jul 09, 2012: Sanofi-Aventis Withdraws Marketing Authorization Application For Mulsevo 78
Jul 09, 2012: FDA Grants Priority Review For Bayer’s XARELTO Supplemental NDAs 78
Jun 25, 2012: Boehringer Ingelheim's Pradaxa Exhibits No Significant Difference In Risk Of Acute Coronary Syndrome In Comparison With Enoxaparin For Prevention Of Venous Thromboembolism 80
Jun 20, 2012: Boehringer Ingelheim Announces Launch Of First Study To Evaluate Alternative To Warfarin For Mechanical Heart Valve Patients 82
Jun 18, 2012: RE-LY Sub-Analysis Suggests Pradaxa Associated With Similar Bleeding Rates And Thromboembolic Complications In Surgery Versus Warfarin 83
May 31, 2012: NICE Recommends Bayer's Xarelto To Treat Blood Clots 85
May 25, 2012: European Medicines Agency Updates Patient And Prescriber Information For Pradaxa 86
May 02, 2012: Janssen Submits XARELTO Applications To FDA For Treatment And Prevention Of Recurrent Venous Thromboembolism 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89
List of Tables
Number of Products Under Development for Venous Thromboembolism, H2 2012 8
Products under Development for Venous Thromboembolism – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Bristol-Myers Squibb Company, H2 2012 20
Sanofi-Aventis, H2 2012 21
Daiichi Sankyo Company, Ltd, H2 2012 22
Bayer AG, H2 2012 23
Portola Pharmaceuticals, Inc., H2 2012 24
Cristalia Produtos Quimicos Farmaceuticos Ltda., H2 2012 25
Endotis Pharma, H2 2012 26
Regado Biosciences., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Venous Thromboembolism Therapeutics – Drug Profile Updates 58
Venous Thromboembolism Therapeutics – Discontinued Products 73
Venous Thromboembolism Therapeutics – Discontinued Products (Contd..1) 74
Venous Thromboembolism Therapeutics – Dormant Products 75
Venous Thromboembolism Therapeutics – Dormant Products (Contd..1) 76
List of Figures
Number of Products under Development for Venous Thromboembolism, H2 2012 8
Products under Development for Venous Thromboembolism – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Thromboembolism Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Venous Thromboembolism 8
Venous Thromboembolism Therapeutics under Development by Companies 10
Venous Thromboembolism Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Venous Thromboembolism Therapeutics – Products under Development by Companies 18
Venous Thromboembolism Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Venous Thromboembolism Therapeutics Development 20
Bristol-Myers Squibb Company 20
Sanofi-Aventis 21
Daiichi Sankyo Company, Ltd 22
Bayer AG 23
Portola Pharmaceuticals, Inc. 24
Cristalia Produtos Quimicos Farmaceuticos Ltda. 25
Endotis Pharma 26
Regado Biosciences. 27
Venous Thromboembolism – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Lixiana - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Eliquis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Betrixaban - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AVE5026 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AVE5026 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Xarelto - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
EP37151 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
REG2 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Dalteparin Sodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Aspirin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Actiparin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Warfarin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Dalteparin Sodium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Fondaparinux - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Aspirin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Sodium Enoxaparin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Rivaroxaban - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Venous Thromboembolism Therapeutics – Drug Profile Updates 58
Venous Thromboembolism Therapeutics – Discontinued Products 73
Venous Thromboembolism Therapeutics - Dormant Products 75
Venous Thromboembolism – Product Development Milestones 77
Featured News & Press Releases 77
Jul 25, 2012: NICE Recommends Bayer's Xarelto For Treatment Of Blood Clots 77
Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Pradaxa 78
Jul 09, 2012: Sanofi-Aventis Withdraws Marketing Authorization Application For Mulsevo 78
Jul 09, 2012: FDA Grants Priority Review For Bayer’s XARELTO Supplemental NDAs 78
Jun 25, 2012: Boehringer Ingelheim's Pradaxa Exhibits No Significant Difference In Risk Of Acute Coronary Syndrome In Comparison With Enoxaparin For Prevention Of Venous Thromboembolism 80
Jun 20, 2012: Boehringer Ingelheim Announces Launch Of First Study To Evaluate Alternative To Warfarin For Mechanical Heart Valve Patients 82
Jun 18, 2012: RE-LY Sub-Analysis Suggests Pradaxa Associated With Similar Bleeding Rates And Thromboembolic Complications In Surgery Versus Warfarin 83
May 31, 2012: NICE Recommends Bayer's Xarelto To Treat Blood Clots 85
May 25, 2012: European Medicines Agency Updates Patient And Prescriber Information For Pradaxa 86
May 02, 2012: Janssen Submits XARELTO Applications To FDA For Treatment And Prevention Of Recurrent Venous Thromboembolism 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89
List of Tables
Number of Products Under Development for Venous Thromboembolism, H2 2012 8
Products under Development for Venous Thromboembolism – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Bristol-Myers Squibb Company, H2 2012 20
Sanofi-Aventis, H2 2012 21
Daiichi Sankyo Company, Ltd, H2 2012 22
Bayer AG, H2 2012 23
Portola Pharmaceuticals, Inc., H2 2012 24
Cristalia Produtos Quimicos Farmaceuticos Ltda., H2 2012 25
Endotis Pharma, H2 2012 26
Regado Biosciences., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Venous Thromboembolism Therapeutics – Drug Profile Updates 58
Venous Thromboembolism Therapeutics – Discontinued Products 73
Venous Thromboembolism Therapeutics – Discontinued Products (Contd..1) 74
Venous Thromboembolism Therapeutics – Dormant Products 75
Venous Thromboembolism Therapeutics – Dormant Products (Contd..1) 76
List of Figures
Number of Products under Development for Venous Thromboembolism, H2 2012 8
Products under Development for Venous Thromboembolism – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32
